Nektar Therapeutics | NKTR - Selling And Administration Expenses


Nektar Therapeutics reported $11.87M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Agios Pharmaceuticals USD 51.55M 13.09M Jun/2026
ALKERMES USD 190.54M 6.1M Sep/2026
Alterity Therapeutics Limited AUD 1.45M 703.96K Dec/2025
Amgen USD 1.68B 40M Sep/2026
Baxter International USD 730M 5M Sep/2026
BioCryst Pharmaceuticals USD 63.98M 31.8M Jun/2026
Biogen USD 752M 42.3M Sep/2026
Bristol-Myers Squibb USD 1.7B 127M Sep/2026
Cara Therapeutics USD 2.09M 96K Mar/2026
Cipla INR 13.25B 101.8M Dec/2025
Dr.Reddys Laboratories INR 26.1B 11.63B Jun/2026
Eisai JPY 114.83B 4.71B Jun/2026
Eli Lilly USD 3.12B 305M Sep/2026
Exelixis USD 154.56M 6.93M Sep/2026
Gilead Sciences USD 1.52B 70M Jun/2026
GlaxoSmithKline GBP 2.16B 39M Sep/2026
Grifols EUR 320.45M 12.65M Dec/2025
Halozyme Therapeutics USD 58.24M 1.24M Sep/2026
Incyte USD 364.27M 12.54M Sep/2026
Ionis Pharmaceuticals USD 130.07M 20.92M Jun/2026
Ironwood Pharmaceuticals USD 33.33M 2.78M Dec/2024
Karyopharm Therapeutics USD 10.42M 861K Mar/2026
MacroGenics USD 7.9M 1.81M Jun/2026
Merck USD 2.86B 25M Sep/2026
Nektar Therapeutics USD 11.87M 1.7M Mar/2026
Neurocrine Biosciences USD 366.3M 16.8M Sep/2026
Novartis USD 3.08B 163M Sep/2026
Pfizer USD 3.28B 132M Sep/2026
Roche Holding CHF 6.37B 908M Jun/2026
Sarepta Therapeutics USD 118.61M 11.01M Sep/2026
Takeda JPY 271.71B 14.8B Sep/2026
Teva Pharmaceutical Industries USD 1.01B 27M Sep/2026
Xencor USD 71.93M 5.61M Sep/2026